EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Regulatory Review Duration and Differences in Submission Times of Drugs in the United States and Europe, 2011 to 2020

Kerstin N Vokinger iD, Miquel Serra-Burriel iD, Camille E G Glaus, Ulrich-Peter Rohr iD, Thomas J Hwang, Simon Dalla Torre di Sanguinetto iD, Aaron S Kesselheim iD

Annals of Internal Medicine · 2023

DOI: 10.7326/m23-0623 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Annals of Internal Medicine, 2023. Verfasst von Kerstin N Vokinger und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Law, University of Zurich, Zurich, Switzerland, and Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiol…. Hauptthemen laut MEDLINE: Drug Approval. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The speed of drug regulatory agencies in the United States and Europe is often a source of discussion. The objective of this research was to assess regulatory review duration of first and supplementary indications approved between 2011 and 2020 in the United States and Europe (European Union [EU] and Switzerland) and differences in submission times between the United States and Europe. Descriptive statistics were applied to review times between the jurisdictions and across the therapeutic areas. A regression analysis was done to estimate the association between approval agency and review times. The primary analysis cohort included 241 drugs approved in the United States, the EU, and Switzerland. Of these, 128 drugs had supplemental indications (331 in total) in the United States and 87 had supplemental indications (206 in total) in the EU. Overall median review duration from submission to approval subtracting the clock stop period was 39 weeks in the United States, 44 weeks in the EU, and 44 weeks in Switzerland. When review times within each drug were compared, the European Medicines Agency took a median of 3.7 weeks (IQR, -6.7 to 14.9 weeks) longer than the U.S. Food and Drug Administration and Swissmedic a median of 0.3 weeks (IQR, -10.6 to 15.3 weeks) longer. Median total review duration for supplemental indications was 26 weeks in the United States and 40 weeks in the EU. Applications were submitted a median of 1.3 and 17.9 weeks later in the EU and Switzerland, respectively, than in the United States. The regression analysis showed small differences in submission times between the United States and the EU (-2.1 weeks [95% CI, -11.7 to 7.6 weeks]) and larger differences between the United States and Switzerland (33.0 weeks [CI, 23.1 to 42.8 weeks]). It would be beneficial for patients if differences in submission times between the United States and Europe continue to be minimized.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug ApprovalHumansUnited StatesPharmaceutical PreparationsEuropeSwitzerlandEuropean UnionUnited States Food and Drug Administration

Substanzen

Pharmaceutical Preparations

Autor:innen und Institutionen

  • Institute of Law, University of Zurich, Zurich, Switzerland, and Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Me…
  • Institute of Law and Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland (M.S.).
  • Institute of Law, University of Zurich, Zurich, Switzerland (C.E.G.G.).
  • Swissmedic, Swiss Agency for Therapeutic Products, Bern, Switzerland (U.-P.R., S.D.T.S.).
  • Division of Urological Surgery, Brigham and Women's Hospital, Harvard Medical School, and Cancer Innovation and Regulation Initiative, Lank Center for Genitourinary Cancer, Boston, Massachusetts (T.J.H.).
  • Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (A.S.K.).

ORCID-Profile: Kerstin N Vokinger, Miquel Serra-Burriel, Ulrich-Peter Rohr, Simon Dalla Torre di Sanguinetto, Aaron S Kesselheim

Zitieren

APA

Vokinger, K. N., Serra-Burriel, M., Glaus, C. E. G., Rohr, U. P., Hwang, T. J., Dalla Torre di Sanguinetto, S., & Kesselheim, A. S. (2023). Regulatory Review Duration and Differences in Submission Times of Drugs in the United States and Europe, 2011 to 2020. Annals of Internal Medicine. https://doi.org/10.7326/m23-0623

Vancouver

Vokinger KN, Serra-Burriel M, Glaus CEG, Rohr UP, Hwang TJ, Dalla Torre di Sanguinetto S, et al. Regulatory Review Duration and Differences in Submission Times of Drugs in the United States and Europe, 2011 to 2020. Annals of Internal Medicine. 2023. doi:10.7326/m23-0623

BibTeX
@article{Vokinger2023,
  author = {Vokinger, Kerstin N and Serra-Burriel, Miquel and Glaus, Camille E G and Rohr, Ulrich-Peter and Hwang, Thomas J and Dalla Torre di Sanguinetto, Simon and Kesselheim, Aaron S},
  title = {Regulatory Review Duration and Differences in Submission Times of Drugs in the United States and Europe, 2011 to 2020},
  journal = {Annals of Internal Medicine},
  year = {2023},
  doi = {10.7326/m23-0623}
}
Kostenlos starten →